Your session is about to expire
← Back to Search
CSF Analysis for Non-Small Cell Lung Cancer
Study Summary
This trial is evaluating a way to find out if systemic therapy is more effective if it can target the correct molecular aberration by looking at molecular differences between cerebral spinal fluid and blood circulating tumor DNA.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am 18 years old or older.I cannot have a lumbar puncture due to low platelets, bleeding issues, or cannot consent.My lung cancer has a specific EGFR mutation and has spread.My blood and organs are functioning well enough for tests.My MRI shows a condition in my spine that makes lumbar puncture unsafe.I can care for myself but may not be able to do heavy physical work.My cancer has spread to the lining of my brain or spinal cord.
- Group 1: Experimental arm
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is there an opportunity for new participants to join this clinical experiment?
"As outlined on clinicaltrials.gov, this investigation is still recruiting participants. The original post was made on July 18th 2022 and the entry has been updated as recently as that same date."
To what extent is this experiment being conducted with human subjects?
"Affirmative. Clinicaltrials.gov shows that the study, which was initially posted on July 18th 2022 and most recently amended on July 18th 2022, is actively seeking participants for its trial with 10 individuals being recruited from a single medical centre."
Share this study with friends
Copy Link
Messenger